Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy …

THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present several studies related to brodalumab, Enbrel (etanercept) and ABP 501 (adalimumab biosimilar) at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to delivering medicines that may help to improve the lives of people suffering from devastating dermatologic diseases.

"As a pioneer in psoriasis research and development, we are pleased to share scientific insights from our growing dermatology portfolio that may help improve care for the millions of people worldwide1 affected by this serious skin disease," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The data being presented at this year's congress demonstrate the breadth and depth of our biologics expertise in advancing treatments that address critical unmet needs for patients living with psoriasis."

Brodalumab data to be presented include an exploratory analysis of the Phase 2 trial evaluating efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis patients with prior biologic exposure, along with an analysis from the open-label extension study of that same Phase 2 study evaluating patient response to treatment after nearly three years. Brodalumab is being co-developed by Amgen and AstraZeneca. Kyowa Hakko Kirin, which has an exclusive license to develop and commercialize brodalumab in Japan, China and certain other Asian countries, will present efficacy and safety data from its Phase 2 study evaluating brodalumab in Japanese patients with moderate-to-severe plaque psoriasis.

ENBREL data focus on step-down dosing compared with a high-dose regimen and patient-reported outcomes of treatment with ENBREL compared to treatment with ENBREL in combination with topical therapies. Additional data include the functional equivalence of proposed biosimilar ABP 501 to adalimumab and an analysis of the incidence of symptoms such as itching and pain in patients with psoriasis.

SELECTED ABSTRACTS OF INTERESTAbstracts are available to registered journalists at http://www.eadvamsterdam2014.org/press and updated data will be presented at the meeting.

Brodalumab Abstracts of Interest

ENBREL (Amgen-sponsored) Abstracts of Interest

Biosimilars Abstracts of Interest

Additional Abstracts of Interest

About Psoriasis Psoriasis is a non-contagious chronic disease in which the immune system causes skin cells to grow at an accelerated rate.2 Instead of being shed, skin cells pile up, causing painful and itchy, red, scaly patches.3 Approximately 125 million people worldwide have psoriasis, and 80 percent of those patients have plaque psoriasis.1,4

See the rest here:
Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy ...